Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer.

J Contemp Brachytherapy · 2022 · PMC8867235 · PMID 35233229

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Despite the potential benefit of HDR-BT and EBRT combination therapy, a decreasing trend in utilization of this treatment approach has been observed in intermediate- and high-risk PC patients [ 9 , 10 ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.